• Submit to Cancers Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• About
• Open Access Policy

• Abstract
• Full-Text PDF [269 KB]

• Article Statistics
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Wargovich, M
• Brown, V
• Morris, J
• [+] on Google Scholar
• Wargovich, M
• Brown, V
• Morris, J
• [+] on PubMed
• Wargovich, M
• Brown, V
• Morris, J

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Cancers 2010, 2(3), 1705-1716; doi:10.3390/cancers2031705

Review

Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer

Michael J. Wargovich* , Vondina R. Brown and Jay Morris

Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Hollings Cancer Center, Medical University of South Carolina, Charleston SC 29425 USA

* Author to whom correspondence should be addressed.

Received: 28 August 2010 / Accepted: 14 September 2010 / Published: 16 September 2010

(This article belongs to the Special Issue Biomarkers: Oncology Studies)

Download PDF Full-Text [269 KB, uploaded 16 September 2010 09:38 CEST]

Abstract: Aberrant crypt foci (ACF) are one of the earliest histopathological manifestations of colon cancer. In this review, we critically present the molecular, cellular, histopathological, and chemopreventive evidence that ACF are relevant biomarkers for colon cancer. The laboratory and clinical evidence are highly suggestive that ACF are in the pathway leading to colon cancer, but not all ACF will do so. The possible fate and outcome of ACF in the progression toward colon cancer may be dependent on a number of features that define their predictive power for the prevention or progression of cancer.

Keywords: aberrant crypt foci; biomarker; colon cancer; chemoprevention

Article Statistics

Cite This Article